Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Orion

89.85 EUR+1.76 %21.10. klo 18.29
14,527 following

ORNBV

NASDAQ Helsinki

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
+1.76 %
+10.25 %
+19.48 %
+19.56 %
+41.16 %
+33.11 %
+142.90 %
+145.09 %
+700.09 %

Orion operates in the pharmaceutical industry. The company conducts research and development of human and veterinary drugs, where the main focus is on diseases that affect the nervous system, as well as oncology and respiratory diseases. Today, the company's products are found on a global level, with the largest presence in the Nordic region and the rest of Europe. The company's head office is located in Espoo, Finland.

Read more
Market cap
12.68B EUR
Turnover
19.54M EUR
P/E (adj.) (26e)
EV/EBIT (adj.) (26e)
P/B (26e)
EV/S (26e)
Dividend yield-% (26e)
Coverage
Recommendation
Accumulate
Target price
Updated
20.07.2026
Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
A positive profit warning for a change: Sisäpiiritieto: Orion parantaa näkymäarviota vuodelle 2026 | Kauppalehti Orion Corporation raises its full-year 2026 outlook for both net sales and operating profit. Orion’s royalty income has grown faster than expected during the first nine...
yesterday
by NukkeNukuttaja
41
Incredibly great performance. Hats off and congratulations to all shareholders Not many Finnish companies have a track record like this to show off: People sometimes ask where Finland’s next Nokia is. When talking about large companies, names like Nokia, Nordea, and Kone usually ...
13 hours ago
by Ummon
19
Orion Prepares for Pharmaceutical Growth with a Major Investment Among other things, the production of active pharmaceutical ingredients and quality assurance will be strengthened. According to Juhani Kankaanpää, who is responsible for Orion’s production and supply chain, the investment...
10/4/2026, 1:15 PM
by Dissidentti
12
Inderes Ensimmäinen potilas on saanut hoitoa Orion Pharman Faasi 1/2 -tutkimuksessa... ORION OYJ LEHDISTÖTIEDOTE 05.10.2026 KLO 15.00 Ensimmäinen potilas on saanut hoitoa Orion Pharman Faasi 1/2 -tutkimuksessa ODM-216-molekyylillä, joka on yhtiön ensimmäinen kliiniseen kehitysvaiheeseen...
10/5/2026, 12:51 PM
by veronmaksaja
9
[quote="veronmaksaja, post:804, topic:557"]\nOrion is paying a pretty steep price for buying back its shares. I doubt that buying at current prices is timed very wisely, or what do others think?\n[/quote]\n\nThis share buyback program isn’t a form of profit distribution; instead,...
9/26/2026, 12:31 PM
by Ilkka
8
Here are Siltanen’s comments on Orion’s positive profit warning Orion announced on Tuesday that it is raising its revenue and earnings guidance for the current year. The driver behind this is faster-than-expected royalty revenue growth, which in practice points to strong traction...
17 hours ago
by Sijoittaja-alokas
6
Here are Antti’s comments on the latest news, as the biological cancer drug candidate advances to the clinical phase. Inderes – 6 Oct 26 Orionin ensimmäinen biologinen syöpälääkeaihio etenee kliiniseen vaiheeseen -... Tutkimus selvittää aihion turvallisuutta ja alustavaa tehoa.
10/6/2026, 5:04 AM
by Sijoittaja-alokas
5
Read more on our forum
Antti Siltanen
Antti Siltanen

Analyst

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
28.10.
2026

Interim report Q3'26

17.2.
2027

Annual report '26

23.3.
2027

General meeting '27

Regulatory press release20.10.2026 klo 20.20

Inside information: Orion upgrades full-year outlook for 2026

Orion
Press release14.10.2026 klo 09.00

Orion publishes Interim Report for January–September 2026 and holds a webcast on 28 October 2026

Orion
Regulatory press release07.10.2026 klo 09.00

125,000 Orion Corporation A shares converted into B shares

Orion

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release06.10.2026 klo 09.00

Orion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European market

Orion
Press release05.10.2026 klo 15.00

Orion Pharma announces first patient dosed in Phase 1/2 clinical trial of ODM-216, the company’s first biologic candidate to reach clinical testing

Orion
Regulatory press release30.09.2026 klo 09.05

Orion Corporation completed share acquisitions

Orion
Regulatory press release30.09.2026 klo 09.00

Orion Corporation: Acquisition of own shares during week 40, 2026

Orion
Regulatory press release25.09.2026 klo 19.00

Orion Corporation: Acquisition of own shares during week 39, 2026

Orion
Regulatory press release18.09.2026 klo 19.00

Orion Corporation: Acquisition of own shares during week 38, 2026

Orion
Regulatory press release11.09.2026 klo 19.00

Orion Corporation: Acquisition of own shares during week 37, 2026

Orion
Regulatory press release04.09.2026 klo 19.00

Orion Corporation: Acquisition of own shares during week 36, 2026

Orion
Regulatory press release04.09.2026 klo 09.00

102,000 Orion Corporation A shares converted into B shares

Orion
Regulatory press release27.08.2026 klo 13.00

Orion Corporation to commence acquisition of own shares for its share-based incentive plans

Orion
Regulatory press release10.08.2026 klo 14.05

Orion’s license partner Tenax Therapeutics’ Phase 3 LEVEL trial of oral levosimendan in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) did not reach its primary endpoint

Orion
Orion, Webcast, Q2'26
Webcast17.07.2026 klo 14.00

Orion, Webcast, Q2'26

Orion
Regulatory press release17.07.2026 klo 12.00

Orion Group Half-Year Financial Report January–June 2026

Orion
Regulatory press release17.07.2026 klo 10.30

Orion Corporation’s financial reporting and Annual General Meeting in 2027

Orion
Regulatory press release15.07.2026 klo 09.00

45,611 Orion Corporation A shares converted into B shares

Orion
Press release03.07.2026 klo 09.00

Orion publishes Half-Year Report for January–June 2026 and holds a webcast on 17 July 2026

Orion
Press release30.06.2026 klo 08.00

Orion Pharma announces agreement with Shilpa Medicare for nivolumab biosimilar for European market

Orion